Boston Scientific
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 10K+ Employees
View Company Info for Free
Overview
Headquarters
300 Boston Scientific Way, Marlborough, ...Phone Number
(508) 683-4000Website
www.bostonscientific.comRevenue
$20.6 BillionStock Symbol
BSXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
5
3
3
2
1
About Boston Scientific
Boston Scientific Corporation is a global medical device company headquartered in Marlborough, Massachusetts, specializing in the development, manufacture, and commercialization of minimally invasive technologies across multiple interventional specialties. Operating through MedSurg and Cardiovascular segments, the company provides advanced solutions such as catheters, stents, and cardiac devices to healthcare providers worldwide, supporting improved patient outcomes and clinical efficiency.Explore more
Boston Scientific Org Chart
AB
Group Controller Latin America
SS
Reporting Analyst
LS
Controller
DS
Data Controller
RM
Global Operations Vice President, Controller
FA
Controller - Southern Cone
BD
Vice President, Finance & Head Electrophysiol...
SG
Credit Controller
RC
Engineer Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Boston Scientific your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Boston Scientific recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Boston Scientific
Website visits: Recent activity has been detected on your website
Check if Boston Scientific has recently received funding, and reach out quickly before it becomes old news!
Check out if Boston Scientific is spiking on competitors!
Click to see if Boston Scientific had a recent Job posting/layoffs
Boston Scientific, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Boston Scientific launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Boston Scientific has new funding data
Recommended Actions
Reach out to Masked Content who joined Boston Scientific as Masked Content
Find 3 more new buyers
Compare Similar Companies to Boston Scientific
Compare insights from companies similar to Boston Scientific, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Boston Scientific
$20.6B
10K+
Public
$400M
1979
DB
Daniel BrennanExecutive Vice President & Chief Financial Officer
Company Profile Activity
Activity Insights
Boston Scientific is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Boston Scientific is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Boston Scientific.
Boston Scientific financials insights
Gather financial insights about Boston Scientific, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1992
Stock Offering
$400M
Boston Scientific Tech Stack
A closer look at the technologies used by Boston Scientific
Most Recent Scoops
Product Launch
Boston Scientific has announced plans to launch PRECEDENT, a new defibrillator platform, in the second half of 2027, aimed at addressing portfolio gaps in its Cardiac Rhythm Management business. Boston Scientific anticipates full-year CRM growth to be flat, with slight improvement in the second half of 2026 supported by the full launch of LUPRA.
Product Launch
Pain Point
Boston Scientific has reported that its Watchman business is experiencing a sharp and unexpected slowdown in the U.S. market, primarily driven by compounding clinical evidence that has impacted referral patterns, resulting in revenue growth below the company's weighted average market growth rate and limited adjusted EPS growth. This slowdown is a concentrated driver of Boston Scientific's overall guidance reduction.
Earnings, Finance
Product Launch
Boston Scientific has announced plans to launch Farawave Ultra, a high-density mapping and ablation catheter, along with its entry into the intracardiac echocardiography market, with further improvement anticipated in 2028 upon the availability of Faraflex, a novel large focal high-density mapping and ablation catheter.
Product Development, Product Launch
Pain Point
Boston Scientific has identified two primary drivers of the overall Left Atrial Appendage Closure market slowdown: a significant volume of clinical evidence on stroke risk in atrial fibrillation patients published over the last nine months that is impacting patient identification and referral patterns, and inefficiencies created by the rapid adoption of concomitant procedures that are hindering sustained growth across both standalone and concomitant segments.
Pain Point
Pain Point
Forecasting
Boston Scientific News & Media
Here’s What Hurt Boston Scientific Corporation (BSX) in Q2
TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]Boston Scientific Director Habiger Buys $100k of Shares Amid 54% Decline. What Does This Mean for BSX in 2026?
Habiger's $100,000 purchase expanded his direct holdings by 14%, signaling confidence despite the stock's recent weakness. The acquisition came as shares traded near their lowest levels in over a year.Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?
Mahoney expanded his equity stake by 13% following a -54% one-year stock decline. His combined holdings now total ~1.6 million shares valued at $78.08 million.Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Boston Scientific
Sign Up For FreeTo access detailed company insights
Boston Scientific Corporation is a global medical device company headquartered in Marlborough, Massachusetts, specializing in the development, manufacture, and commercialization of minimally invasive technologies across multiple interventional specialties. Operating through MedSurg and Cardiovascular segments, the company provides advanced solution... Read More
